225 Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
University Hospital Heidelberg · Heidelberg University · +4 more institutions
Indexed incrossrefpubmed
Abstract
Results
Both patients experienced a prostate-specific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect.
Conclusion
Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.
Citation impact
1,078
total citations
- FWCI
- 58.61
- Percentile
- 100%
- References
- 17
Citations per year
Authors
10- CKClemens KratochwilCorresponding
University Hospital Heidelberg, Heidelberg University
- FBFrank Bruchertseifer
Joint Research Centre
- FLFrederik L. Giesel
University Hospital Heidelberg, Heidelberg University
- MWMirjam Weis
Joint Research Centre
- FAFrederik A. Verburg
RWTH Aachen University, Universitätsklinikum Aachen
Topics & keywords
Topics
Keywords
- Prostate cancer
- Medicine
- Glutamate carboxypeptidase II
- Toxicity
- Radionuclide therapy
- Prostate
- Oncology
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.